Avanir Pharmaceuticals (Nasdaq:AVNR) announced that A recent survey from PricewaterhouseCoopers found that life sciences firms believe that industry-FDA relationships have bettered since Obama took office. In fact, 80% of those surveyed said in the last two years the FDA has provided better guidance about its expectations.
Better guidance leads to fewer letdowns for drug manufacturers, and less risk for speculative investors. The Bedford Report examines the outlook for companies in the Drug Manufacturers-Others Industry and provides research reports on Arena Pharmaceuticals, Inc. and Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR). Access to the full company reports can be found at: bedfordreport.com/2010-12-ARNA.
AVANIR Pharmaceuticals, Inc. focuses on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States and Canada.
MusclePharm Appoints Former Bristol-Myers Squibb Executive as Director of Therapeutic Nutrition
- Clinical Studies to Determine the Effects of MusclePharm's Top Selling Product Assault(NYSE:R)
MusclePharm(R) Corporation (OTC:MSLP) , one of the fastest growing nutritional supplement companies in the United States, yesterday announced the appointment of Michael R. Stevens, PharmD as Director of Therapeutic Nutrition.
Dr. Stevens joins MusclePharm with over twenty years of well diversified experience in the healthcare and pharmaceutical industry.
In addition to his current role as Chief Strategy Officer for Virostatics, Dr. Stevens spent 17 years at Bristol-Myers Squibb, where he held positions of increasing responsibility in the areas of Market Research (Oncology and HIV), Marketing (Oncology), and Medical Affairs (HIV).
"We are extremely pleased to have Dr. Stevens join the MusclePharm team and further strengthen our position in working to add MusclePharm's Re-con(R) and MuscleGel(R) nutritional supplements to the New York State Medicaid list of prescription medications," commented Dr. Roscoe Moore, former United States Surgeon General, and Chief Science Director for MusclePharm. "With Dr. Stevens' extensive experience and assistance, we plan to further MusclePharm's support of therapeutic nutritional supplementation in the medical community."
Headquartered in Denver, Colorado, MusclePharm is a rapidly expanding healthy life-style company that develops and manufactures a full line of NSF and scientifically approved nutritional supplements that are 100% free of any banned substances. Based on years of research, MusclePharm products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than 100 elite professional athletes from various sports including the NFL, MMA, and MLB.
The Company's propriety and award winning products address all categories of an active lifestyle including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen.
MusclePharm is sold in over 120 countries and available in over 5,000 U.S. retail outlets that include GNC, and Vitamin Shoppe, as well as over 100 online stores, including bodybuilding.com, Amazon and Vitacost.com.
Aviat Networks, Inc. (Nasdaq:AVNW) the municipal electric utility for the City of Santa Clara, announced that Aviat Networks, Inc. will participate in its clean renewable energy program, Santa Clara Green Power. Aviat Networks will purchase one-half of the output of one large-scale wind turbine on an annual basis.
Aviat Networks entered a two-year green power purchase commitment as part of its initiative to achieve LEED Gold Certification for its new Santa Clara facility. Derived from clean wind and solar generation sources, Aviat Networks' renewable power commitment -- 1504 megawatt-hours annually -- makes Aviat Networks a member of the U.S. EPA's Green Power Partnership for its Santa Clara facility.
Aviat Networks, Inc. engages in the design, manufacture, and sale of a range of wireless networking products, solutions, and services worldwide. The company offers a product portfolio that addresses the needs of service providers and network operators addressing a range of applications.
Gold Mining in Colombia, the next faze of economic development but for whom… Orofino Gold Corp. (ORFG.PK) is a China based gold producer with one producing gold mine in Colombia and an option on a strong portfolio of small producers and development/exploration assets in Colombia. Orofino Gold was founded as a private company in 2009 by former executives and management with over 50 years of combined mining exploration, finance and development experience.
Orofino’s corporate objective is to continue to build shareholder value through the exploration and development of existing projects and additional accretive acquisitions, capitalizing on the extensive experience and relationships that management has developed over the past 25 years.
Orofino Gold Corp. is a US (Nevada) company established for the purpose of creating a significant exploration and mining group to operate in Colombia. Orofino has major criteria by which they select properties that include: Significant historical production; Favorable geology for hosting major ore bodies; Significant property area for large target exploration; Recent results available; Favorable infrastructure and access to allow mine development; and Receptive local government and populace.
In addition Orofino has acquired a database comprised of exploration and mining results from previous operators who left when the global mining sector experienced a major downturn in the three year period from 1997-2000. The second part of Orofino Gold’s strategy to become a recognized player in the Colombia mining sector was the acquisition of an interest in an operating mine. Orofino has acquired a 55% interest in the La Azul/La Estrella property with the rights to acquire up to 80%.
Axcelis Technologies Inc. (Nasdaq:ACLS) a leading supplier of innovative, high-productivity solutions for the semiconductor industry, is pleased to announce that Mary Puma, chairman and CEO, will be presenting at the Small Cap Ideas Conference sponsored by David L. Kanen, vice president of institutional sales at First Midwest Securities, Inc. This year's conference will be held December 16 at the Harvard Club in New York, New York. Puma will be presenting on December 16 at 11:30 a.m. ET. For those who cannot attend, the conference will be available via live Webcast, and archived for 90 days, at www.axcelis.com.
Axcelis Technologies, Inc. designs, manufactures, and services ion implantation, dry strip, and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe, and the Asia Pacific.
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more at http://crwepicks.com/disclaimer ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.
Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for 30 (thirty) days of advertising for MusclePharm Corporation (OTCQB:MSLP).
Crown Equity Holdings Inc. (OTCPK:CRWE) has received 500,000 shares of 144 stock in Orofino Gold Corp. (PINK SHEETS: ORFG) valued at sixty five thousand dollars, and 500,000 shares of free trading shares valued at sixty five thousand dollars from a third party (QU CUI You) for 30 days advertising.